On October 8, the stock prices of many A-share pharmaceutical companies fell significantly. Specifically, Alice fell 20%, Lizhu Group fell 10%, Yahong Pharmaceuticals fell by more than 11%, and Yifang Biotech, and Sansheng Guojian fell more than 7%. The industry generally believes that the cause of this collective decline in the innovative drug sector is negative news about the failure of the phase III clinical trial of the domestic innovative pharmaceutical company Alice.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.